ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022
SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- SARS-CoV-2 IgG seropositivity among people living with and without HIV in the first year of the COVID-19 pandemic in Haiti and Tanzania.IJID regions · 2026Article
- Review
- A longitudinal study of antibody responses to endemic HCoV and novel SARS-CoV-2 among mother-child pairs in Zambia.BMC infectious diseases · 2025Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Coronavirus Disease 2019 Vaccination Trends: Findings from Surveillance Conducted at First Antenatal Care Visits in Kenya, Nigeria, Malawi, Mozambique, Uganda, and Zambia, 2021-2022.The American journal of tropical medicine and hygiene · 2025Article
- Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.PloS one · 2025Article
- Parametric survival analysis of long COVID among hospitalized patients in Zambia: A retrospective cohort study on the time to symptoms resolving.PLOS global public health · 2025Article
- Article
- Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits in Zambia: A repeated cross-sectional survey, 2021-2022.PLOS global public health · 2024Article
- High anti-SARS-CoV-2 seroprevalence among unvaccinated mother-child pairs from a rural setting in north-eastern Tanzania during the second wave of COVID-19.IJID regions · 2023Article
- Seroprevalence survey of anti-SARS-CoV-2 antibody and associated factors in South Africa: Findings of the 2020-2021 population-based household survey.PLOS global public health · 2023Article
- Seroprevalence survey of SARS-CoV-2, community behaviors, and practices in Kansanshi and Kalumbila mining towns.Frontiers in public health · 2023Article
- Facilitators and barriers to COVID-19 testing in community and clinical settings: Lessons learned from Lesotho and Zambia.PLOS global public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWe nested a seroprevalence survey within the TREATS (Tuberculosis Reduction through Expanded Antiretroviral Treatment and Screening) project. We aimed to measure the seroprevalence of SARS-CoV-2 infection and investigate associated risk factors in one community (population ∼27,000) with high prevalence of TB/HIV in Zambia.
methodsThe study design was cross-sectional. A random sample of 3592 individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing. Randomly selected blocks of residence were visited between October 2020 and March 2021. Antibodies against SARS-CoV-2 were detected using Abbott- ARCHITECT SARS-CoV-2 IgG assay.
resultsA total of 3035/3526 (86.1%) individuals had a blood sample taken. Antibody testing results were available for 2917/3035 (96.1%) participants. Overall, 401/2977 (13.5%) individuals tested positive for IgG antibodies. Seroprevalence was similar by sex (12.7% men vs 14.0% women) and was lowest in the youngest age group 15-19 years (9.7%) and similar in ages 20 years and older (∼15%). We found no evidence of an association between seroprevalence and HIV-status or TB. There was strong evidence (p <0.001) of variation by time of enrollment, with prevalence varying from 2.8% (95% CI 0.8-4.9) among those recruited in December 2020 to 33.7% (95% CI 27.7-39.7) among those recruited in mid-February 2021.
conclusionSeroprevalence was 13.5% but there was substantial variation over time, with a sharp increase to approximately 35% toward the end of the second epidemic wave.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.